News/Research on HIV/AIDS Medication Selzentry (Maraviroc, Celsentri)

See also: Selzentry (Maraviroc, Celsentri) Main Page

Conference Update From IAS 2011: Medication News (September/October 2011)
To read PDF, click here.
In Positively Aware, from Test Positive Aware Network
Paediatric Antiretroviral Pipeline: Update on Etravirine and Maraviroc (July/August 2011)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
Maraviroc Plus Atazanavir/r Without Nukes Versus Standard of Care: 48-Week Results (July/August 2011)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
Selzentry Reduces Liver Stiffness in HIV/HCV-Coinfected Patients (July 21, 2011)
From AIDSmeds.com
Maraviroc Improves Liver Fibrosis in HIV/Hepatitis C Co-Infected Patients (July 20, 2011)
From aidsmap.com
Etravirine Lowers Levels of Maraviroc Given at 300 or 600 mg Twice Daily (May/June 2011)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
Once-Daily 150-mg Maraviroc Explored in People Taking Atazanavir/Ritonavir (May/June 2011)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
Indian Drugmaker Seeks to Make, Sell Generic Version of Pfizer's HIV Drug (January 5, 2011)
In Kaiser Daily Global Health Policy Report, from Henry J. Kaiser Family Foundation
Long-Term Outcomes Good After Coreceptor Switch in Maraviroc Failure (September 15, 2010)
From National AIDS Treatment Advocacy Project
People With X4 Virus Who Failed Selzentry Have Good Long-Term Results (September 14, 2010)
From AIDSmeds.com
Small Study Suggests Once-Daily MVC Plus ATV/r as Viable First Regimen (July 26, 2010)
From National AIDS Treatment Advocacy Project
Fewer Malignancies Seen in Those Taking Selzentry (July 20, 2010)
From AIDSmeds.com
Selzentry Labeling Includes New Warnings for People With Kidney Problems: A Blog Entry by Myles Helfand (June 2, 2010)
From The Body
Selzentry (Maraviroc) 150 mg and 300 mg Tablets, Labeling Changes for Patients With Renal Impairment (June 1, 2010)
From U.S. Food and Drug Administration
Maraviroc Approved for First-Line Therapy (Winter/Spring 2010)
To read PDF, click here.
In Bulletin of Experimental Treatments for AIDS, from San Francisco AIDS Foundation
Maraviroc Showing Tantalising Promise as Microbicide in Preclinical Studies (February 19, 2010)
From aidsmap.com
Maraviroc Does Not Boost Stalled CD4s in Virologically Suppressed People (February 18, 2010)
From National AIDS Treatment Advocacy Project
Selzentry Now for First-Timers (January/February 2010)
In Positively Aware, from Test Positive Aware Network
Maraviroc Gets FDA Nod as First-Line Antiretroviral in U.S. (November 20, 2009)
From U.S. Food and Drug Administration
U.S. FDA Panel Backs Wider Use of Pfizer HIV Drug (October 9, 2009)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
Pfizer HIV Drug Seems Safe for New Use -- FDA Staff (October 7, 2009)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
Maraviroc Levels in Female Genital Tract May Support Drug's Potential in HIV Prophylaxis (August 2009)
In Journal of Acquired Immune Deficiency Syndromes
Early Tests of Maraviroc as Microbicide Produce Less Activity Than Expected (July 23, 2009)
Preclinical ex-vivo tests of the entry inhibitor drug maraviroc as a possible microbicide have found that the drug only produced a moderate protective effect against HIV: a 50% to 60% inhibition of HIV infection of penile tissue and an 85% inhibition in colorectal tissue, when given at high doses.
From aidsmap.com
Genetic Test Predicts Response to Maraviroc in Treatment-Experienced HIV Patients (July 22, 2009)
To read PDF, click here.
From British Columbia Centre for Excellence in HIV/AIDS
Maraviroc Looks Better With New Trofile Test (Winter/Spring 2009)
In Bulletin of Experimental Treatments for AIDS, from San Francisco AIDS Foundation
Traditional Approval and Label Changes for Selzentry (Maraviroc) (December 4, 2008)
From U.S. Food and Drug Administration
IPM Reaches Landmark Agreement With Pfizer to Develop FDA-Approved Antiretroviral Drug as Vaginal Microbicide (January 30, 2008)
From International Partnership for Microbicides
ICAAC: Maraviroc Failures Associated With Shifts From R5-Tropic to Mixed or X4-Tropic HIV (September 20, 2007)
From aidsmap.com
IAS: Maraviroc Produces Best Results When Combined With Another Active Drug (August 14, 2007)
From aidsmap.com
Clinical Data Show Pfizer's Antiretroviral Maraviroc Reduces HIV Viral Loads Among Treatment-Naive People, Company Says (July 26, 2007)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
Maraviroc Underperforms Efavirenz in Treatment-Naive Study (July 25, 2007)
In 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, from The Body PRO
European Advisory Panel Recommends Approval of Pfizer's Antiretroviral Maraviroc, Company Says (July 23, 2007)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
Pfizer Advises Maraviroc Dose Increase if Combined With Etravirine (July 20, 2007)
From aidsmap.com
Held Up in U.S., First CCR5 Inhibitor Nears Approval in Europe (July 20, 2007)
From aidsmap.com
Maraviroc Approval Is Delayed in United States (June 21, 2007)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
Treatment Action Group Supports Maraviroc Approval (May 1, 2007)
From Treatment Action Group
FDA Panel Recommends Agency Approve Pfizer's Antiretroviral Maraviroc (April 25, 2007)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
CROI: Maraviroc Shows Potent Effect in Highly Treatment-Experienced (February 28, 2007)
From aidsmap.com
Phase 3 Results of Two Key Trials of Maraviroc, the First-in-Class CCR5 Antagonist (February 27, 2007)
In Exclusive Coverage of the 14th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Maraviroc + OBT Potent in Treatment-Experienced HIV-Infected Patients: An Interview With Roy Gulick, M.D. (February 27, 2007)
In Exclusive Coverage of the 14th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
FDA Panel to Consider Pfizer's Second-Line HIV Drug (February 9, 2007)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
The Next HIV Therapies (February 2007)
MK-0518, TMC125 and Maraviroc.
In HIV JournalView, from The Body PRO
United States: Pfizer to Expand Access to HIV Drug (December 5, 2006)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
HIV Antiretroviral Agents in Development: Entry Inhibitors (March 30, 2006)
From The Body
Once-Daily Arm in Maraviroc Treatment-Naive Study Terminated (January 30, 2006)
From aidsmap.com
Case Study of a Patient With Serious Hepatotoxicity in Maraviroc 2b/3 Trial Reported at Targeting HIV Entry -- 1st International Workshop (December 3, 2005)
[Archived Article]
To read PDF, click here.
From Pfizer, Inc.
The CCR5 Antagonist UK-427,857 (Maraviroc) Shows Strong Activity in Phase 1/2a Monotherapy Studies (July 26, 2005)
[Archived Article]
In The 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment
Entry Inhibitors in Development (July 2004)
[Archived Article]
Brief updates on PRO 542, SCH-D, UK-427,857 and GW-873140.
To read PDF, click here.
In Project Inform Perspective, from Project Inform